Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAptitude Regulatory News (APTD)

Share Price Information for Aptitude (APTD)

Share Price is delayed by 15 minutes
Get Live Data
218.00    -4.00 (-1.80%)
Bid:
218.00
Ask:
229.00
Spread: 11.00 (5.046%)
Market Cap: £115.09m
APTD Live PriceLast checked at - London Stock Exchange

Intraday Aptitude Share Chart

AGM Trading Update

18 May 2015 07:00

RNS Number : 3380N
Microgen PLC
18 May 2015
 



microgen

www.microgen.com 18 May 2015

 

 

MICROGEN PLC

AGM TRADING UPDATE

 

Martyn Ratcliffe, Chairman of Microgen plc ("Microgen" or the "Group"), will provide the following trading update at the Annual General Meeting to be held at 9.00am this morning.

 

"The Board is pleased to confirm that the results for the four months ended 30 April 2015 are ahead of the comparable period in 2014 and ahead of the Board's expectations and plans for the current year.

 

The Group maintains good visibility of its full year revenue with 84% of total planned revenue for 2015 already contracted and 95% of current year revenue expected to be generated from this customer base. This high level of forward revenue visibility is derived from the Group's annual licensing model.

 

Aptitude Software is progressing satisfactorily, with increased services demand in the year to date and a good pipeline of new business opportunities, particularly for the Aptitude Revenue Recognition Engine, an Aptitude-based finance application which addresses the IFRS 15 accounting requirements. Microgen Financial Systems has also continued its success with the 5Series Trust & Fund Administration product and has successfully completed the integration of the Unity acquisition.

 

Following the completion of the £20 million B/C Share Scheme in April 2015, Microgen has now returned £70 million to shareholders since October 2008. In line with the Group's seasonal cash flow cycle, the Group had cash at 30 April 2015 of £18.6 million (31 December 2014: £40.9 million) and net funds of £3.1 million (31 December 2014: £24.6 million).

 

In summary, the Board are pleased with the start to the year and anticipate continuing the Group's track record of resilient financial performance.

 

Following the Group's Preliminary Results announcement in February, the Board received an unsolicited approach from a UK private equity organisation which, following a period of due diligence, resulted in a proposal to acquire the Aptitude Software business. While the proposal provided an affirmation of the Group's market valuation and the Aptitude strategy/potential, the Board did not consider this proposal to be in the best interests of Microgen shareholders and discussions were therefore terminated."

 

 

With regard to the Board succession announced in February, Martyn Ratcliffe has advised the Board that he will be retiring as a Director after the release of the interim results in July but will remain an employee of the Group until the end of September to provide a transition. In accordance with his personal investment practice, Mr Ratcliffe has informed the Board that he will be realising his 17 year investment in Microgen and the Board will be working closely with the Company's broker, Investec, to place this holding with institutional shareholders in a timely manner. The process to appoint a new Chairman is underway and an announcement will be made in due course.

 

 

Contacts

Martyn Ratcliffe, Chairman 020-7496-8100

Philip Wood, Group Finance Director

 

Andrew Pinder, Investec 020-7597-4000

 

Lucy Delaney, FTI Consulting 020-3727-1131

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAAMBTMBJBBPA
Date   Source Headline
25th Mar 201110:10 amRNSBlock Listing Return
24th Mar 201112:22 pmRNSAnnual Information Update
2nd Mar 201110:11 amRNSHolding(s) in Company
28th Feb 201110:15 amRNSTotal Voting Rights
25th Feb 201111:53 amRNSDirector/PDMR Shareholding
24th Feb 20117:00 amRNSFinal Results
16th Feb 20113:18 pmRNSNotice of Results
3rd Feb 20115:00 pmRNSHolding(s) in Company
3rd Feb 20114:58 pmRNSHolding(s) in Company
28th Jan 201112:59 pmRNSHolding(s) in Company
17th Jan 20114:18 pmRNSDirector Declaration
14th Jan 20114:18 pmRNSHolding(s) in Company
10th Jan 20117:00 amRNSPre-close Trading Update
7th Jan 201111:49 amRNSBlocklisting Return
7th Jan 201111:48 amRNSBlocklisting Return
4th Jan 201110:10 amRNSTotal Voting Rights
4th Nov 20107:00 amRNSDirector/PDMR Shareholding
3rd Nov 20103:40 pmRNSHolding(s) in Company
29th Oct 201010:00 amRNSTotal Voting Rights
26th Oct 20107:00 amRNSInterim Management Statement
26th Oct 20107:00 amRNSInterim Management Statement
30th Sep 20107:00 amRNSTotal Voting Rights
29th Sep 20108:05 amRNSDirector/PDMR Shareholding
27th Sep 20107:01 amRNSBlocklisting Interim Review
23rd Sep 201010:59 amRNSApplication for Blocklisting
15th Sep 20107:00 amRNSMicrogen Aptitude Modules Launch
9th Sep 20102:37 pmRNSHolding(s) in Company
6th Sep 201012:38 pmRNSHolding(s) in Company
2nd Sep 20104:32 pmRNSHolding(s) in Company
31st Aug 20101:19 pmRNSTotal Voting Rights
23rd Aug 20102:12 pmRNSDirector/PDMR Shareholding
23rd Aug 20107:00 amRNSResult of Tender Offer
19th Aug 201010:09 amRNSGM Announcement
11th Aug 201011:16 amRNSHolding(s) in Company
2nd Aug 20101:15 pmRNSPosting of Shareholder Circular
26th Jul 201012:49 pmRNSHolding(s) in Company
22nd Jul 20107:00 amRNSInterim Results
14th Jul 20103:30 pmRNSNotice of Results
1st Jul 201012:51 pmRNSBlocklisting Interim Review
1st Jul 201012:46 pmRNSBlocklisting Interim Review
24th Jun 20104:35 pmRNSDirector/PDMR Shareholding
3rd Jun 20104:38 pmRNSHolding(s) in Company
1st Jun 20102:14 pmRNSDirector Declaration
4th May 20109:57 amRNSTotal Voting Rights
27th Apr 201012:26 pmRNSDirector/PDMR Shareholding
23rd Apr 20102:41 pmRNSDirector/PDMR Shareholding
22nd Apr 20107:00 amRNSInterim Management Statement
16th Apr 20101:56 pmRNSDirector Declaration
22nd Mar 201010:03 amRNSAGM Statement
18th Mar 201011:33 amRNSAnnual Information Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.